{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:52:37Z","timestamp":1793969557239,"version":"4.8.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"\n PURPOSE<\/jats:title>\n \n Methylthioadenosine phosphorylase (\n MTAP<\/jats:italic>\n ) genomic loss is an emerging biomarker for PRMT5 and MAT2A inhibitors based on synthetic lethality. The\n MTAP<\/jats:italic>\n gene is located on chromosome 9p21.3 near\n CDKN2A\/B. MTAP<\/jats:italic>\n homozygous loss across tumor types, specific exons lost,\n MTAP<\/jats:italic>\n expression, and the landscape of coalterations were assessed.\n <\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n \n 409,755 tissue biopsies (TBx) and 85,801 liquid biopsies (LBx) were sequenced using hybrid capture\u2013based NGS (FoundationOne CDx or FoundationOne Liquid CDx), evaluating all classes of genomic alterations and circulating tumor DNA (ctDNA) tumor fraction (TF). Additionally, 6,740 TBx were subjected to both RNA and DNA sequencing to compare MTAP gene expression with genomic\n MTAP<\/jats:italic>\n loss<\/jats:sub>\n .\n <\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n \n The prevalence of pan-tumor\n MTAP<\/jats:italic>\n loss<\/jats:sub>\n was 11.4% using TBx, with the highest prevalence observed in mesothelioma (32.8%), glioma (32.7%), pancreatic (28.9%), and bladder cancers (26.4%). Prevalence of\n MTAP<\/jats:italic>\n loss<\/jats:sub>\n on LBx approximated that of TBx when ctDNA TF \u226520% (positive percent agreement [PPA] = 86.2%).\n CDKN2A<\/jats:italic>\n loss<\/jats:sub>\n was not a reliable proxy for\n MTAP<\/jats:italic>\n loss<\/jats:sub>\n ; 33.7% of\n CDKN2A<\/jats:italic>\n loss<\/jats:sub>\n cases did not have\n MTAP<\/jats:italic>\n \n loss<\/jats:italic>\n <\/jats:sub>\n .\n MTAP<\/jats:italic>\n loss<\/jats:sub>\n was enriched with\n CDKN2A\/B<\/jats:italic>\n losses pan-tumor,\n EGFR<\/jats:italic>\n in NSCLC,\n ERBB2<\/jats:italic>\n in colorectal cancer, and\n PTEN<\/jats:italic>\n in prostate cancer, while\n MTAP<\/jats:italic>\n \n no_<\/jats:italic>\n <\/jats:sub>\n loss<\/jats:sub>\n was enriched for\n RB1<\/jats:italic>\n pan-tumor,\n APC<\/jats:italic>\n in colorectal cancer,\n CCNE1<\/jats:italic>\n in breast and ovarian cancer, and\n SPOP<\/jats:italic>\n in prostate cancer. Complete loss (exons 1-8) was observed in 82.9%, multiple exons in 16.5% and exon 8 alone in <1%.\n MTAP<\/jats:italic>\n loss<\/jats:sub>\n , specifically the number of exons lost, was correlated with reduced RNA expression.\n <\/jats:p>\n <\/jats:sec>\n \n CONCLUSION<\/jats:title>\n \n MTAP<\/jats:italic>\n loss<\/jats:sub>\n is a frequent pan-tumor alteration that predicts potential sensitivity to PRMT5 or MAT2A inhibitors. Although most tumors exhibit complete\n MTAP<\/jats:italic>\n loss<\/jats:sub>\n , 16.5% are characterized by partial\n MTAP<\/jats:italic>\n loss<\/jats:sub>\n where clinical benefit remains uncertain. The genomic coalteration landscape reported here may inform future PRMT5 or MAT2A clinical trials, potentially in combination with other agents.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/po-26-00037","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T19:59:11Z","timestamp":1778788751000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Genomics of\n MTAP<\/i>\n Loss in >500,000 Solid Tumor Specimens Profiled Using Comprehensive Genomic Profiling Platforms"],"prefix":"10.1200","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-6246","authenticated-orcid":true,"given":"Dean C.","family":"Pavlick","sequence":"first","affiliation":[{"name":"Department of Computational Discovery, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0102-9597","authenticated-orcid":true,"given":"Shruthi","family":"Rengarajan","sequence":"additional","affiliation":[{"name":"Department of Computational Discovery, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-5092","authenticated-orcid":true,"given":"Jessica K.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-1580","authenticated-orcid":true,"given":"Dexter X.","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Computational Discovery, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2361-2750","authenticated-orcid":true,"given":"Garrett M.","family":"Frampton","sequence":"additional","affiliation":[{"name":"Department of Computational Discovery, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7352-0689","authenticated-orcid":true,"given":"Bernard J.","family":"Fendler","sequence":"additional","affiliation":[{"name":"Department of Computational Biology, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Savol","sequence":"additional","affiliation":[{"name":"Department of Computational Biology, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-8769","authenticated-orcid":true,"given":"Ole","family":"Gjoerup","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-7555","authenticated-orcid":true,"given":"Hanna","family":"Tukachinsky","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8395-5168","authenticated-orcid":true,"given":"Richard S.P.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0106-9096","authenticated-orcid":true,"given":"Alexa B.","family":"Schrock","sequence":"additional","affiliation":[{"name":"Department of Clinical Development, Foundation Medicine, Inc, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-2596","authenticated-orcid":true,"given":"Jeffrey S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Department of Pathology, Foundation Medicine, Inc, Boston, MA"},{"name":"Departments of Pathology, Medicine (Oncology), and Urology, Upstate Medical University, Syracuse, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":true,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS San Raffaele Hospital, Comprehensive Cancer Center, Milan, Italy"},{"name":"Vita-Salute San Raffaele University, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-2126(99)80084-7"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)69835-2"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.9.2665"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5637-0_16"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(81)90024-6"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08822"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408593102"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(95)00157-3"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104535"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0669"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5214"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI81749"},{"key":"e_1_3_6_14_2","volume-title":"Summary of Safety and Effectiveness Data (SSED) for Foundationone CDx (F1CDx), PMA No. P170019\/S054","author":"US Food and Drug Administration","year":"2025","unstructured":"US Food and Drug Administration: Summary of Safety and Effectiveness Data (SSED) for Foundationone CDx (F1CDx), PMA No. P170019\/S054, 2025"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138"},{"key":"e_1_3_6_17_2","volume-title":"Summary of Safety and Effectiveness Data (SSED) for FoundationOne Liquid CDx, PMA No P190032\/S011","author":"US Food and Drug Administration","year":"2023","unstructured":"US Food and Drug Administration: Summary of Safety and Effectiveness Data (SSED) for FoundationOne Liquid CDx, PMA No P190032\/S011, 2023"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2018.05.004"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.163"},{"key":"e_1_3_6_21_2","article-title":"Clinical presentation of MTAP deletions in real-world settings: Lessons for the clinical development of novel targeted therapies","author":"Best JT","unstructured":"Best JT, Fu X, Jampana Raju SS, et al: Clinical presentation of MTAP deletions in real-world settings: Lessons for the clinical development of novel targeted therapies. JCO Precis Oncol 10.1200\/PO-25-00564","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae011"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-462"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.10.001"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00286-4"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00443-5"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100966"},{"key":"e_1_3_6_28_2","article-title":"Prognostic role of MTAP loss in cholangiocarcinoma","author":"Lyon J","unstructured":"Lyon J, Osataphan S, Birda V, et al: Prognostic role of MTAP loss in cholangiocarcinoma. JCO Precis Oncol 10.1200\/PO-24-00842","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0887"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.BLADDER24-B027"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3011"},{"key":"e_1_3_6_32_2","volume-title":"PRMT5: Bench to bedside. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Plenary Session 8","author":"Crystal AS","year":"2025","unstructured":"Crystal AS: PRMT5: Bench to bedside. Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Plenary Session 8, 2025"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-26-00037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:39:05Z","timestamp":1779287945000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-26-00037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1200\/PO-26-00037"],"URL":"https:\/\/doi.org\/10.1200\/po-26-00037","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"2026-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2600037"}}